Biosite(R) Incorporated Announces Exclusive License for Cardiovascular Marker
August 22 2005 - 9:00AM
PR Newswire (US)
Company Licenses Caspase-1 From Johannes Gutenberg University,
Mainz, Germany SAN DIEGO, Aug. 22 /PRNewswire-FirstCall/ --
Biosite(R) Incorporated (NASDAQ:BSTE) today announced it has signed
an exclusive license with Johannes Gutenberg University, Mainz,
Germany for Caspase-1, a potentially important cardiovascular
disease biomarker. Under the terms of the license agreement,
Biosite is collaborating with the University of Mainz to
investigate possible clinical applications for the biomarker. The
financial terms of the agreement were not disclosed. "Each year,
cardiovascular diseases top the list of the country's most serious
health problems, and although Biosite has commercialized products
on the market addressing cardiovascular diseases, it is an
important area of ongoing investigation for our Biosite Discovery
program," said Gunars Valkirs, Ph.D., Biosite's senior vice
president Biosite Discovery. About Biosite Incorporated Biosite
Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis.
The Company's products contribute to improvements in medical care
by aiding physicians in the diagnosis of critical diseases and
health conditions. Biosite's Triage(R) rapid diagnostics are used
in approximately 50 percent of U.S. hospitals and in over 50
international markets. Information on Biosite can be found at
http://www.biosite.com/. Except for the historical information
presented herein, matters discussed in this press release are
forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such statements. Statements that are not historical facts,
including but not limited to statements that are preceded by,
followed by, or that include the words "will"; "believes";
"should"; "intends"; "anticipates"; "plans"; "expects";
"estimates"; or similar statements are forward-looking statements.
Forward looking statements include statements about the possible
clinical applications for caspase-1 in the field of cardiovascular
diseases and Biosite's ability to evaluate the diagnostic utility
of the target. Risks that should be considered include risks and
uncertainties regarding the discovery and product development
process generally, risks associated with the introduction of
competitive products from companies with greater capital and
resources, uncertainties around the proprietary nature of the
targets subject to the collaboration, expansion or development of a
direct sales effort in domestic and international markets, and
risks and expenses associated with litigation, contract disputes,
patent conflicts, product recalls, manufacturing constraints,
backlog, delays or inefficiencies, shipment problems, seasonal
customer demand, the timing of significant orders, changes in
reimbursement policies, regulatory changes, competitive pressures
on average selling prices, and the other risks detailed in
Biosite's most recent Annual Report on Form 10-K, as amended, and
other SEC filings. Biosite disclaims, any intent or obligation to
update these forward-looking statements. Copies of Biosite's public
disclosure filings are available from its investor relations
department. Biosite(R), Triage(R) and New Dimensions in
Diagnosis(R) are registered trademarks of Biosite Incorporated. The
Company's logo is a trademark of Biosite Incorporated. DATASOURCE:
Biosite Incorporated CONTACT: Nadine Padilla, VP, Corporate &
Investor Relations of Biosite Incorporated, +1-858-455-4808, ext.
3187, Web site: http://www.biosite.com/ Company News On-Call:
http://www.prnewswire.com/comp/116737.html
Copyright
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2023 to Jul 2024